# Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Study · id `cardio:ct-nct05714085` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05714085](<https://clinicaltrials.gov/study/NCT05714085>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05714085

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 342 participants.

## Technical summary

Registry record NCT05714085. Randomized; quadruple masking; primary purpose treatment. Start 2023-05-31 (actual); primary completion 2029-08-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 342 participants (planned count; ClinicalTrials.gov record NCT05714085, source copy `cardio:ctgov-nct05714085-2026-11-13`, retrieved 2026-11-18)
- Started: 2023-05-31 (actual) (ClinicalTrials.gov record NCT05714085, source copy `cardio:ctgov-nct05714085-2026-11-13`, retrieved 2026-11-18)
- Primary completion: 2029-08-20 (anticipated) (ClinicalTrials.gov record NCT05714085, source copy `cardio:ctgov-nct05714085-2026-11-13`, retrieved 2026-11-18)
- Completion: 2032-05-12 (anticipated) (ClinicalTrials.gov record NCT05714085, source copy `cardio:ctgov-nct05714085-2026-11-13`, retrieved 2026-11-18)
- Countries: United States; Belgium; Brazil; Canada; Colombia; Croatia; Denmark; Finland; France; Germany; Hungary; Ireland; Italy; Malaysia; Mexico; Netherlands; New Zealand; Peru; Poland; Portugal; Saudi Arabia; Serbia; Singapore; South Africa; South Korea; Spain; Sweden; Thailand; Türkiye; United Kingdom (ClinicalTrials.gov record NCT05714085, source copy `cardio:ctgov-nct05714085-2026-11-13`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05714085-2026-11-13`, retrieved 2026-11-18)

## The registry's words

- Brief title: Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- Condition: Heart Failure
- Condition: Left Ventricular Systolic Dysfunction
- Intervention (Drug): Vericiguat tablet
- Intervention (Drug): Vericiguat suspension
- Intervention (Drug): Placebo tablet
- Intervention (Drug): Placebo suspension
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

## Provenance

Content hash: 1b6cd7aa5e5c89f487939e0fcd5b16db6761faee2afa49e19699630d77971c59
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
